Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Regulatory Approval

Tandem Diabetes Care Shares Surge 15% After FDA 510(k) Clearance for Tubeless Mobi Pump

Tandem Diabetes Care (TNDM) Receives FDA 510(k) Clearance for Tubeless Mobi Insulin Pump

+15.02% $17.51 when we broke this story → $20.14 at 1:33 PM ET, 13 Nov 2026

Tandem Diabetes Care has secured FDA 510(k) clearance for its Tandem Mobi pump, enabling a new tubeless infusion option with up to seven days of wear. This regulatory milestone transitions the device into the world's first hybrid system offering both tubed and tubeless delivery configurations.

Old, petrol, pump, automotive. Stock photo illustrating Tandem Diabetes Care's regulatory approval story.
TANDEM DIABETES CARE INC · Healthcare · Photo: photoeightyeight / Pixabay

Key highlights

  • FDA 510(k) clearance granted for the Tandem Mobi tubeless cartridge and infusion set
  • System supports up to 7 days of wear for the infusion set and 3 days for the cartridge
  • Full commercial launch scheduled for the first half of 2027 in the United States
  • Integrated with Control-IQ technology for advanced hybrid closed-loop insulin delivery
  • Tandem Mobi becomes the only pump on the market offering users a choice between wear styles

What Approval Was Received?

Tandem Diabetes Care received U.S. Food and Drug Administration (FDA) 510(k) clearance for a new tubeless cartridge and infusion set for its Tandem Mobi system. This clearance transforms the existing Mobi platform into the first automated insulin delivery (AID) system capable of functioning as both a traditional tubed pump and a tubeless wearable. The newly approved infusion set is cleared for up to seven days of wear, while the associated cartridge is cleared for three days of use. This flexibility allows patients to switch between wear styles depending on their daily needs or activity levels.

TANDEM DIABETES CARE INC share price · last month
Line chart of TANDEM DIABETES CARE INC's share price over the last month, from $16.38 on 19 Oct → $18.48 on 16 Nov; our story on 13 Nov at $17.51.

Up 5.5% since our story on 13 Nov: $17.51 when we broke it → $18.48 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$16.38
20 Oct$16.52
21 Oct$16.35
22 Oct$17.15
23 Oct$17.43
26 Oct$18.90
27 Oct$19.22
28 Oct$19.68
29 Oct$19.79
30 Oct$19.11
2 Nov$18.67
3 Nov$17.65
4 Nov$19.05
5 Nov$17.99
6 Nov$16.91
9 Nov$18.17
10 Nov$18.71
11 Nov$18.77
12 Nov$17.51
13 Nov$20.07
16 Nov$18.48

Why This Approval Matters

  • Eliminates the requirement for permanent tubing, addressing a major preference for users seeking discreet insulin delivery.
  • Introduces the only dual-modality pump in the diabetes tech market, providing a competitive alternative to single-use patch pumps.
  • Leverages established Control-IQ hybrid closed-loop technology to automate insulin delivery based on glucose levels.
  • Extends the infusion set wear time to seven days, reducing the frequency of site changes for patients.

Path to Market

Following the FDA clearance, Tandem Diabetes Care plans a phased approach toward commercial availability. A full commercial launch of the tubeless cartridge and infusion set is slated for the first half of 2027 within the United States. This timeline allows the company to scale its manufacturing and supply chain operations for the new components. The Mobi pump itself is already a flagship in Tandem portfolio, and this update expands its addressable market by targeting the significant segment of insulin users who prefer tubeless patch style devices over traditional hardware.

Business Overview

Headquartered in San Diego, Tandem Diabetes Care is a medical device manufacturer focused on insulin delivery for people with type 1 diabetes. The company reported annual revenue of approximately $1.01 billion, supported by its t:slim X2 pump and the more recent Mobi platform. By integrating with continuous glucose monitors like the Dexcom G6 and G7, Tandem has established a strong presence in the automated insulin delivery sector. The addition of a tubeless option places the company in direct competition with specialized patch-pump manufacturers while maintaining its legacy tubed-pump market share.

TANDEM DIABETES CARE INC · financial snapshot
Share price$17.51
Market cap$1.2B
Revenue (annual)$1.0B
1-month price change+5.17%
SectorHealthcareMedical Devices

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Tandem Diabetes Care, Inc. announcing FDA 510(k) clearance for Tandem Mobi.

Read the filing ↗

Track TANDEM DIABETES CARE INC live

Get the next TANDEM DIABETES CARE INC SEC filing seconds after it lands.

More in Approvals

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.